Login  
Research Report
 
India
Aarti Industries
Ajanta Pharma
Apcotex Industries
Atul Ltd
Aurobindo Pharma
Bharat Forge
Biocon
Camlin Fine Sciences
Cipla
Dabur India Ltd
Dishman Pharma
Divis Laboratories
Dr Reddys Lab
Eris Lifesciences
Glenmark Pharma
Indonesia Outlook
IPCA Laboratories
Jubilant Foodworks
Jubilant Life Science
Lupin
Meghmani Organics Ltd
Shilpa Medicare
SRF Ltd
Sun Pharma
Syngene International
Thyrocare Technologies Ltd
Vinati Organics
Zydus Lifescience
Zydus Wellness
 
Home >> Country >> India >> Company
Company Name : Sun Pharma
Y/E Mar, Rs mn FY11 FY12 FY13 FY14E FY15E
Price798
Target638
RecoNEU
Net Sales57,21680,054112,389160,372179,198
Growth (%)40404312
EBIDTA19,63132,67650,40272,28576,001
EBITDA Margin41454542
Net Profit17,80327,21136,33753,52652,590
Growth (%)533447-2
EPS, Rs913182625
PER, x92.860.745.530.931.4
EV/EBIDTA, x8350322221
P/BV, x17141197
ROE, % 1922243123
Total debt/Equity (%)-18.8-24.9-25.3-26.6-25.0
Latest Reports
Date Description Country Analyst Download
01-Feb-2024 Sun Pharma - In line performance and visible triggers priced-in; Downgrade to Neutral with TP Rs 1370 India Surya Patra
02-Nov-2023 Sun Pharma - Core operating performance remains strong; Maintain BUY with the pre-fixed TP of Rs 1250 India Surya Patra
04-Aug-2023 Sun Pharma - Continued outperformance in core operations; Maintain BUY with TP Rs 1250 India Surya Patra
29-May-2023 Sun Pharma - Margin challenges seem receding; Upgrade to BUY with raised TP of Rs 1100 India Surya Patra
01-Feb-2023 Sun Pharma - Margin challenges crept in; Downgrade to Neutral with TP Rs 1000 India Surya Patra
01-Nov-2022 Sun Pharma- Robust core operating performance amid challenges; Maintain BUY with TP Rs 1150 India Surya Patra
01-Aug-2022 Sun Pharma - Strong core performance in difficult times: Maintain BUY with raised TP of Rs 1150 India Surya Patra
31-May-2022 Sun Pharma - Sequential value growth still on cards; Maintain BUY with TP Rs 1050 India Surya Patra
01-Feb-2022 Sun Pharma - US business to drive value growth ahead; BUY with TP Rs 105 India Surya Patra
03-Nov-2021 Sun Pharma - Specialty Biz drives value growth; BUY with TP Rs 1000 India Surya Patra
30-Aug-2021 Sun Pharma - Imminent value growth ahead: BUY with raised TP of Rs 1000 India Surya Patra
01-Aug-2021 Sun Pharma - Sequential value growth on cards; BUY with raised TP of Rs 890 India Surya Patra
22-Jun-2021 Sun Pharma - Revlimid settlement drives multi-year value growth; BUY with raised TP of Rs 825 India Surya Patra
28-May-2021 Sun Pharma - Healthy US Specialty and domestic biz excite: Maintain BUY with TP Rs 770 India Surya Patra
30-Jan-2021 Sun Pharma (SUNP IN) - Specialty business in driver’s seat ; Maintain BUY with TP Rs 710 India Surya Patra
01-Dec-2020 Sun Pharma - US specialty progress to re-rate; BUY with TP Rs 600 India Surya Patra
04-Nov-2020 Sun Pharma - Visible progress in US specialty business excites us: Upgrade to BUY with TP Rs 600 India Surya Patra
03-Aug-2020 Sun Pharma - Challenges look larger than opportunities; Downgrade to Neutral with TP Rs 550 India Surya Patra
28-May-2020 Sun Pharma: Focus on Specialty, India formulations & deleveragi; Maintain BUY with TP Rs 500 India Surya Patra
07-Feb-2020 Sun Pharma (SUNP IN) - All eyes on specialty portfolio’s performance India Surya Patra
07-Nov-2019 Sun Pharma - No near term benefit from its strategic initiatives; Maintain Neutral with TP Rs 450 India Surya Patra
13-Aug-2019 Sun Pharma (SUNP IN) - Operational challenges in specialty business hurts; NEUTRAL with TP Rs 450 India Surya Patra
29-May-2019 Sun Pharma (SUNP IN) - Specialty promotion in the US to pressure earnings; NEUTRAL with TP Rs 450 India Surya Patra
13-Feb-2019 Sun Pharma (SUNP IN) - Specialty business to keep margins under pressure; NEUTRAL with TP of Rs 500 India Surya Patra
13-Nov-2018 Sun Pharma (SUNP IN) - Pinned hopes on the US specialty; Maintain NEUTRAL with TP of Rs 590 India Surya Patra
1 2 3 
Copyright © 2013. Brought to you by PhillipCapital (India) Pvt. Ltd.      Designed and developed by C-MOTS Infotech (ISO 9001:2015 certified)